Sarepta Therapeutics stock rose over 3% pre-market after releasing promising early results for its RNA therapies, SRP-1001 and SRP-1003. The data, targeting rare muscle diseases FSHD1 and DM1, showed encouraging safety and biological activity, potentially overcoming delivery challenges in RNA treatments.